Avicanna Inc. to Present at Life Sciences Investor Forum on September 17
News related to:Avicanna Inc · 2 min read
TORONTO, Sept. 15, 2026 /CourierPR/ -- Avicanna Inc., a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, will present at the Life Sciences Investor Forum on September 17, 2026. The forum, hosted by VirtualInvestorConferences.com, aims to provide investors and industry professionals with an opportunity to engage with management in real-time.
Aras Azadian, CEO of Avicanna Inc., will present at 10:30 am Eastern Time. The event will be conducted as a live, interactive online forum, allowing participants to submit questions directly to the management team. A replay of the webcast will be available after the conference concludes.
Avicanna Inc. is a company dedicated to the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical markets. The company has an established scientific platform, including research and development (R&D) and clinical development, leading to the commercialization of over thirty proprietary, evidence-based finished products. These products support four commercial-stage business pillars.
The first pillar is the Medical Cannabis formulary (RHO Phyto™), which offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. RHO Phyto is an established brand in Canada, currently available nationwide across several channels and expanding into new international markets.
The second pillar is the Medical cannabis care platform (MyMedi.ca), a platform designed to better serve the needs of medical cannabis patients. MyMedi.ca features a diverse portfolio of products and bilingual pharmacist-led patient support programs. It also provides specialty services to distinct patient groups, such as veterans, and collaborates with public and private payers for adjudication and reimbursement.
The third pillar is the Pharmaceutical pipeline, which leverages Avicanna’s scientific platform, vertical integration, and real-world evidence to develop proprietary, indication-specific cannabinoid-based candidates in various stages of clinical development. These candidates aim to address unmet needs in dermatology, chronic pain, and various neurological disorders.
The fourth pillar is Active pharmaceutical ingredients (Aureus Santa Marta™), a commercial-stage business dedicated to providing high-quality CBD, THC, and CBG to Avicanna’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. Aureus Santa Marta also forms part of Avicanna’s supply chain, serving as a reliable source of input products for its consumer retail, medical cannabis, and pharmaceutical products globally.
Avicanna Inc. encourages online investors to pre-register and run the online system check to ensure smooth participation and to receive event updates. More information about the event can be found at www.virtualinvestorconferences.com.